Neonatal abstinence syndrome

Mara G. Coyle, Susan B. Brogly, Mahmoud Ahmed, Stephen W. Patrick, Hendrée E. Jones

Research output: Contribution to journalReview article

1 Citation (Scopus)

Abstract

Neonatal abstinence syndrome refers to the signs and symptoms attributed to the cessation of prenatal exposure (via placental transfer) to various substances. This Primer focuses on neonatal abstinence syndrome caused by opioid use during pregnancy - neonatal opioid withdrawal syndrome (NOWS). As the global prevalence of opioid use has alarmingly increased, so has the incidence of NOWS. NOWS can manifest with varying severity or not at all, for unknown reasons, but is likely to be associated with multiple factors, both maternal (for example, smoking and additional substance exposures) and neonatal (gestational age, sex and genetics). Care for the infant with NOWS begins with addressing the issues experienced by pregnant women with opioid use disorder. Co-occurring mental illness, economic hardship, intimate partner violence, infectious diseases and limited access to care are common in these women and can result in poor maternal and neonatal outcomes. Although there is no consensus regarding optimal NOWS management, non-pharmacological interventions (such as breastfeeding and rooming-in of the mother and the baby) have become a priority, as they can ameliorate symptoms without the need for further opioid exposure. Untreated NOWS can be associated with morbidity in early infancy, and the long-term consequences of fetal opioid exposure are only beginning to be understood.

Original languageEnglish (US)
Number of pages1
JournalNature reviews. Disease primers
Volume4
Issue number1
DOIs
StatePublished - Nov 22 2018

Fingerprint

Neonatal Abstinence Syndrome
Opioid Analgesics
Mothers
Infant Care
Breast Feeding
Gestational Age
Signs and Symptoms
Communicable Diseases

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Coyle, M. G., Brogly, S. B., Ahmed, M., Patrick, S. W., & Jones, H. E. (2018). Neonatal abstinence syndrome. Nature reviews. Disease primers, 4(1). https://doi.org/10.1038/s41572-018-0045-0

Neonatal abstinence syndrome. / Coyle, Mara G.; Brogly, Susan B.; Ahmed, Mahmoud; Patrick, Stephen W.; Jones, Hendrée E.

In: Nature reviews. Disease primers, Vol. 4, No. 1, 22.11.2018.

Research output: Contribution to journalReview article

Coyle, MG, Brogly, SB, Ahmed, M, Patrick, SW & Jones, HE 2018, 'Neonatal abstinence syndrome', Nature reviews. Disease primers, vol. 4, no. 1. https://doi.org/10.1038/s41572-018-0045-0
Coyle, Mara G. ; Brogly, Susan B. ; Ahmed, Mahmoud ; Patrick, Stephen W. ; Jones, Hendrée E. / Neonatal abstinence syndrome. In: Nature reviews. Disease primers. 2018 ; Vol. 4, No. 1.
@article{5fde2df410c245939c3f6e8d0b9d5636,
title = "Neonatal abstinence syndrome",
abstract = "Neonatal abstinence syndrome refers to the signs and symptoms attributed to the cessation of prenatal exposure (via placental transfer) to various substances. This Primer focuses on neonatal abstinence syndrome caused by opioid use during pregnancy - neonatal opioid withdrawal syndrome (NOWS). As the global prevalence of opioid use has alarmingly increased, so has the incidence of NOWS. NOWS can manifest with varying severity or not at all, for unknown reasons, but is likely to be associated with multiple factors, both maternal (for example, smoking and additional substance exposures) and neonatal (gestational age, sex and genetics). Care for the infant with NOWS begins with addressing the issues experienced by pregnant women with opioid use disorder. Co-occurring mental illness, economic hardship, intimate partner violence, infectious diseases and limited access to care are common in these women and can result in poor maternal and neonatal outcomes. Although there is no consensus regarding optimal NOWS management, non-pharmacological interventions (such as breastfeeding and rooming-in of the mother and the baby) have become a priority, as they can ameliorate symptoms without the need for further opioid exposure. Untreated NOWS can be associated with morbidity in early infancy, and the long-term consequences of fetal opioid exposure are only beginning to be understood.",
author = "Coyle, {Mara G.} and Brogly, {Susan B.} and Mahmoud Ahmed and Patrick, {Stephen W.} and Jones, {Hendr{\'e}e E.}",
year = "2018",
month = "11",
day = "22",
doi = "10.1038/s41572-018-0045-0",
language = "English (US)",
volume = "4",
journal = "Nature Reviews Disease Primers",
issn = "2056-676X",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - Neonatal abstinence syndrome

AU - Coyle, Mara G.

AU - Brogly, Susan B.

AU - Ahmed, Mahmoud

AU - Patrick, Stephen W.

AU - Jones, Hendrée E.

PY - 2018/11/22

Y1 - 2018/11/22

N2 - Neonatal abstinence syndrome refers to the signs and symptoms attributed to the cessation of prenatal exposure (via placental transfer) to various substances. This Primer focuses on neonatal abstinence syndrome caused by opioid use during pregnancy - neonatal opioid withdrawal syndrome (NOWS). As the global prevalence of opioid use has alarmingly increased, so has the incidence of NOWS. NOWS can manifest with varying severity or not at all, for unknown reasons, but is likely to be associated with multiple factors, both maternal (for example, smoking and additional substance exposures) and neonatal (gestational age, sex and genetics). Care for the infant with NOWS begins with addressing the issues experienced by pregnant women with opioid use disorder. Co-occurring mental illness, economic hardship, intimate partner violence, infectious diseases and limited access to care are common in these women and can result in poor maternal and neonatal outcomes. Although there is no consensus regarding optimal NOWS management, non-pharmacological interventions (such as breastfeeding and rooming-in of the mother and the baby) have become a priority, as they can ameliorate symptoms without the need for further opioid exposure. Untreated NOWS can be associated with morbidity in early infancy, and the long-term consequences of fetal opioid exposure are only beginning to be understood.

AB - Neonatal abstinence syndrome refers to the signs and symptoms attributed to the cessation of prenatal exposure (via placental transfer) to various substances. This Primer focuses on neonatal abstinence syndrome caused by opioid use during pregnancy - neonatal opioid withdrawal syndrome (NOWS). As the global prevalence of opioid use has alarmingly increased, so has the incidence of NOWS. NOWS can manifest with varying severity or not at all, for unknown reasons, but is likely to be associated with multiple factors, both maternal (for example, smoking and additional substance exposures) and neonatal (gestational age, sex and genetics). Care for the infant with NOWS begins with addressing the issues experienced by pregnant women with opioid use disorder. Co-occurring mental illness, economic hardship, intimate partner violence, infectious diseases and limited access to care are common in these women and can result in poor maternal and neonatal outcomes. Although there is no consensus regarding optimal NOWS management, non-pharmacological interventions (such as breastfeeding and rooming-in of the mother and the baby) have become a priority, as they can ameliorate symptoms without the need for further opioid exposure. Untreated NOWS can be associated with morbidity in early infancy, and the long-term consequences of fetal opioid exposure are only beginning to be understood.

UR - http://www.scopus.com/inward/record.url?scp=85057135695&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85057135695&partnerID=8YFLogxK

U2 - 10.1038/s41572-018-0045-0

DO - 10.1038/s41572-018-0045-0

M3 - Review article

VL - 4

JO - Nature Reviews Disease Primers

JF - Nature Reviews Disease Primers

SN - 2056-676X

IS - 1

ER -